Desmopressin Acetate Patent Expiration

Desmopressin Acetate is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2023. Details of Desmopressin Acetate's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7022340 Pharmaceutical composition as solid dosage form and method for manufacturing thereof
Apr, 2023

(1 year, 5 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Desmopressin Acetate's patents.

Given below is the list of recent legal activities going on the following patents of Desmopressin Acetate.

Activity Date Patent Number
Patent litigations
Expire Patent 30 Apr, 2018 US7022340 (Litigated)
Maintenance Fee Reminder Mailed 13 Nov, 2017 US7022340 (Litigated)
Change in Power of Attorney (May Include Associate POA) 30 May, 2014 US7022340 (Litigated)
Recordation of Patent Grant Mailed 04 Apr, 2006 US7022340 (Litigated)
Patent Issue Date Used in PTA Calculation 04 Apr, 2006 US7022340 (Litigated)
Issue Notification Mailed 15 Mar, 2006 US7022340 (Litigated)
Dispatch to FDC 03 Mar, 2006 US7022340 (Litigated)
Printer Rush- No mailing 02 Feb, 2006 US7022340 (Litigated)
Mail Miscellaneous Communication to Applicant 02 Feb, 2006 US7022340 (Litigated)
Miscellaneous Communication to Applicant - No Action Count 31 Jan, 2006 US7022340 (Litigated)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Desmopressin Acetate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Desmopressin Acetate's family patents as well as insights into ongoing legal events on those patents.

Desmopressin Acetate's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Desmopressin Acetate's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 30, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Desmopressin Acetate Generics:

Desmopressin Acetate is the generic name for the brand Desmopressin Acetate. 24 different companies have already filed for the generic of Desmopressin Acetate, with Abhai Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Desmopressin Acetate's generic

Alternative Brands for Desmopressin Acetate

There are several other brand drugs using the same active ingredient (Desmopressin Acetate) as Desmopressin Acetate. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Acerus Pharms
Noctiva
Ferring Pharms Inc
Ddavp
Ddavp (needs No Refrigeration)
Nocdurna


Apart from brand drugs containing the same ingredient, some generics have also been filed for Desmopressin Acetate, Desmopressin Acetate's active ingredient. Check the complete list of approved generic manufacturers for Desmopressin Acetate





About Desmopressin Acetate

Desmopressin Acetate is a drug owned by Ferring Pharmaceuticals Inc. Desmopressin Acetate uses Desmopressin Acetate as an active ingredient. Desmopressin Acetate was launched by Ferring in 2008.

Approval Date:

Desmopressin Acetate was approved by FDA for market use on 08 May, 2008.

Active Ingredient:

Desmopressin Acetate uses Desmopressin Acetate as the active ingredient. Check out other Drugs and Companies using Desmopressin Acetate ingredient

Dosage:

Desmopressin Acetate is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.1MG TABLET Discontinued ORAL
0.2MG TABLET Discontinued ORAL